# EDGAR Filing Document

**Accession Number:** 0001479419
**File Stem:** 0001829126-26-002931
**Filing Date:** 2026-3
**Character Count:** 8907
**Document Hash:** 0611fcc84c45456a27b9a38d6f4e0b46
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-002931.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001829126-26-002931

**CONFORMED SUBMISSION TYPE**: NT 10-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**EFFECTIVENESS DATE**: 20260331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KALA BIO, Inc.
- **CENTRAL INDEX KEY:** 0001479419
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 270604595
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38150
- **FILM NUMBER:** 26821606

**BUSINESS ADDRESS:**
- **STREET 1:** 1167 MASSACHUSETTS AVENUE
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476
- **BUSINESS PHONE:** 781-996-5252

**MAIL ADDRESS:**
- **STREET 1:** 1167 MASSACHUSETTS AVENUE
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kala Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20091223

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

---

| | |
|:---|:---|
| *(Check One):* | ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR |
|  | For Period Ended: <u>December 31, 2025</u><br>☐ Transition Report on Form 10-K<br> ☐ Transition Report on Form 20-F<br> ☐ Transition Report on Form 11-K<br> ☐ Transition Report on Form 10-Q<br>For the Transition Period Ended: _______________________ |

---

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I - REGISTRANT INFORMATION**

---

| |
|:---|
| KALA BIO, INC. |
| Full name of Registrant |
| Former Name if Applicable |
| 1167 Massachusetts Avenue |
| Address of Principal Executive Office (Street and Number) |
| Arlington, MA 02476 |
| City, State and Zip Code |

---

**PART II - RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

&nbsp;&nbsp;&nbsp;&nbsp;(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition
report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day
following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III - NARRATIVE**

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

KALA BIO, Inc. (the "Company") will not, without unreasonable effort and expense, be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "2025 Annual Report") within the prescribed time period. The Company has undergone certain changes starting in November 2025, including significant director and officer turnover and a strategic transition in its business strategy. Additional time is needed for the Company to compile and analyze supporting documentation in order to complete its financial statement and disclosure preparation and review process to finalize the Form 10-K. The Company anticipates that it will file the Form 10-K no later than the fifteenth calendar day following the prescribed filing date.

**PART IV - OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

---

| | |
|:---|:---|
| **Avi Minkowitz** | **(347) 818-1261** |
| (Name) | (Area Code) (Telephone Number) |

---

---

| | |
|:---|:---|
| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☐ Yes ☒ No |
|  | Form 8-K relating to a promissory note entered into on February 9, 2026. |
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No |

---

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Please refer to Annex A, which is attached to this Form 12b-25 and incorporated by reference herein.

**Special Note Regarding Forward-Looking Statements**. The statements included in or incorporated into this Form 12b-25 regarding our financial performance and results of operations, in each case as expected to be reported, expected filing date of the Form 10-K, and the completion of matters necessary to permit filing by the extension deadline, and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although we believe the expectations and forecasts reflected in our forward-looking statements are reasonable, we can give no assurance they will prove to have been correct. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. Factors that could cause actual results to differ materially from expected results include: (i) unanticipated factors that may delay the Company's completion of its Form 10-K; (ii) the preliminary nature of the financial results contained in this Form 12b-25 and the possibility that such results could materially change as they are finalized and audited; and (iii) other factors described under Risk Factors in our most recent Form 10-K and other filings with the U.S. Securities and Exchange Commission. Unless required by law, the Company expressly disclaims any obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

**<u>KALA BIO, INC.</u>**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | | |
|:---|:---|:---|:---|:---|
| Date: | March 31, 2026 | By: | /s/ Avi Minkowitz | /s/ Avi Minkowitz |
|  |  |  | Name: | Avi Minkowitz |
|  |  |  | Title: | Chief Executive Officer |

---

**Annex A (Pursuant to Part IV, Question 3)**

The Company anticipates reporting a net loss of approximately $27.3 million for 2025, compared to a net loss of approximately $38.5 million for 2024. The anticipated improvement is driven by a gain of approximately $4.6 million from the fair value remeasurement of contingent consideration and a decrease of approximately $3.3 million from reduced research and development, both primarily driven by the Company's decision to cease development of KPI-012 and its MSC-S platform. In addition, the Company anticipates a gain of approximately $5.8 million on extinguishment of debt in connection with the settlement of the Company's loan agreement during the fourth quarter of 2025, and approximately $5.1 million primarily related to settlements of certain executive compensation and other liabilities and a lease settlement. These improvements were partially offset by an increase of approximately $5.6 million in general and administrative expenses, primarily due to higher professional fees and employee-related costs associated with the Company's decision to cease development of KPI-012 and its MSC-S platform, The Company's anticipated results remain subject to the completion of customary year-end closing procedures and audit, and actual results may differ from the preliminary expectations described above.

The Company believes that the results contained herein, are materially correct, however, certain amounts in the financial statements could be revised when the Company files its Annual Report on Form 10-K.